The Oral Transmucosal Drugs market research report covers a worldwide outlook of the industry with specifically studying the manufacturers/ key market players. The historical, current, and forecast sales data provided in the report highlights the market's latest trends and future growth scope. The upcoming trends and anticipated risk factors of the market are also covered in the report giving the holistic prospective of the market. The segmentation by type and application is studied at the country level for the study period 2022 to 2028.
As the global economy mends, the 2021 growth of Oral Transmucosal Drugs will have significant change from previous year. According to this latest study, the global Oral Transmucosal Drugs market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Oral Transmucosal Drugs market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Oral Transmucosal Drugs market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Oral Transmucosal Drugs market, reaching US$ million by the year 2028. As for the Europe Oral Transmucosal Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Oral Transmucosal Drugs players cover LTS Lohmann Therapie-Systeme AG, Soligenix, ZIM Laboratories Limited, and Access Pharmaceutical Inc., etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Transmucosal Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
- Tablets
- Films
- Liquid Spray
- Gels
- Others
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
- Cardiovascular Disorders
- Acute Pain Managements
- Diabetes
- Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
- LTS Lohmann Therapie-Systeme AG
- Soligenix
- ZIM Laboratories Limited
- Access Pharmaceutical Inc.
- C.L Pharm
- Cure Pharmaceutical
- Aquestive Therapeutics, Inc.
- NAL Pharma
- IntelGenx Corp.
- Eisai Co., Ltd.
- Otsuka Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Viatris
- Bristol-Myers Squibb Company